Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552418 · ClinicalTrials.gov registry record · Early Phase 1
Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors
A Early Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT04552418 is a Early Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT04552418, a Early Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a pilot study designed to assess the safety and feasibility of administering a dietary supplement to patients undergoing cancer treatment with a dual immune checkpoint inhibitors (ICIs) for solid cancer.
Interventions
- DRUG Potato starch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2023-01-24 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04552418
The ClinicalTrials.gov registry entry for NCT04552418 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Potato starch is the first listed.
NCT04552418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04552418 about?
NCT04552418 is a clinical study titled "Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors". This is a pilot study designed to assess the safety and feasibility of administering a dietary supplement to patients undergoing cancer treatment with a dual immune checkpoint inhibitors (ICIs) for solid cancer.
What is the current status of trial NCT04552418?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2021-06-02. Estimated completion is 2023-01-24.
What interventions are being tested in trial NCT04552418?
The interventions under investigation include: Potato starch (DRUG).
Who is sponsoring clinical trial NCT04552418?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.